Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs
Authors:
- Simopekka VänskäSVSimopekka Vänskä
- Tapio LuostarinenTLTapio Luostarinen
- Camilla LaghedenCLCamilla Lagheden
- Carina EklundCECarina Eklund
- Sara Nordqvist KleppeSKSara Nordqvist Kleppe
- Bengt AndraeBABengt Andrae
- Pär SparénPSPär Sparén
- Karin SundströmKSKarin Sundström
- Matti LehtinenMLMatti Lehtinen
- Joakim DillnerJDJoakim Dillner
Open Access
- 8 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 190 (4) , 506-514
Abstract
The elimination of cervical cancer rests on high efficacy of human papillomavirus (HPV) vaccines. The HPV type distribution among cases of invasive cervical cancer (ICC) is used to make predictions about the impact of eliminating different types of HPV, but accumulating evidence of differences in age-specific cancer incidence by HPV type exists. We used one of the largest population-based series of HPV genotyping of ICCs (n = 2,850; Sweden, 2002–2011) to estimate age-specific ICC incidence by HPV type and obtain estimates of the cancer-protective impact of the removal of different HPV types. In the base case, the age-specific ICC incidence had 2 peaks, and the standardized lifetime risk (SLTR, the lifetime number of cases per birth cohort of 100,000 females) for HPV-positive ICC was 651 per 100,000 female births. In the absence of vaccine types HPV 16 and HPV 18, the SLTR for ICC was reduced to 157 per 100,000 female births (24% of HPV-positive SLTR). Elimination of all 9 types that can currently be vaccinated against reduced the remaining SLTR to 47 per 100,000 female births (7%), the remaining ICC incidence only slowly increasing with age. In conclusion, after elimination of vaccine-protected HPV types, very few cases of ICC will be left, especially among fertile, reproductive-age women.Keywords
Funding Information
- Swedish Foundation for Strategic Research (KF10-0046)
- Research Council of Finland
- Nordic Academy for Advanced Studies
- Cancerfonden
This publication has 28 references indexed in Scilit:
- Impact of Vaccination on 14 High-Risk HPV Type Infections: A Mathematical Modelling ApproachPLOS ONE, 2013
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2012
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Long-term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical Abnormalities, and Cancer IncidenceEpidemiology, 2011
- Efficient DNA Extraction for HPV Genotyping in Formalin-Fixed, Paraffin-Embedded TissuesThe Journal of Molecular Diagnostics, 2011
- Worldwide burden of cervical cancer in 2008Annals of Oncology, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Prospective Study of Human Papillomavirus (HPV) Types, HPV Persistence, and Risk of Squamous Cell Carcinoma of the CervixCancer Epidemiology, Biomarkers & Prevention, 2010
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialBMJ, 2010
- Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human PapillomavirusJournal of Clinical Microbiology, 2009